OphRx

Company Overview

Snapshot

Founded in January 2014, OphRx operates with 1–10 employees. The company has secured $1 million in total capital across one funding round from four investors. In December 2015, Bio Light's IOPtiMate system, a related entity, received regulatory approval in Canada for glaucoma treatment, indicating broader strategic movements within the parent organization's portfolio.

Business overview

OphRx specializes in developing noninvasive drug delivery solutions for ocular use, leveraging lyotropic liquid crystals as an alternative to traditional methods like intra-vitreal injections. The company's core technology addresses diseases affecting both the back and front of the eye. Currently, OphRx is in the preclinical development stage for two product candidates: OPH-101, a topical treatment for wet AMD, and OPH-100, designed to treat Dry Eye Syndrome (DES). The company operates within the Health Tech & Life Sciences sector, specifically focusing on pharmaceuticals, ophthalmology, and drug delivery technologies.

Strategic signal

In July 2017, BioLight Life Sciences Ltd., the parent company of OphRx, reported successful results from its Phase 1/2a clinical trial for the glaucoma insert VS101. This milestone demonstrates the parent company's capability in advancing ophthalmic treatments through clinical development, signaling a positive environment for OphRx's own preclinical programs in ocular drug delivery.

Company Intelligence Q&A

What is OphRx's primary focus in drug delivery?

OphRx focuses on noninvasive drug delivery for ocular use, utilizing lyotropic liquid crystals as an alternative to conventional methods like intra-vitreal injections for treating eye diseases.

What are OphRx's current product candidates?

OphRx is currently in preclinical development for OPH-101, an alternative topical treatment for wet AMD, and OPH-100, a treatment for Dry Eye Syndrome (DES).

What significant regulatory approval did Bio Light, OphRx's parent company, achieve?

In December 2015, Bio Light Israeli Life Sciences Investments Ltd. received regulatory approval from the Canadian Medical Devices Bureau to commercialize its IOPtiMate system for glaucoma treatment in Canada.

What clinical trial success did BioLight Life Sciences Ltd. announce?

In July 2017, BioLight Life Sciences Ltd. announced successful results from its Phase 1/2a clinical trial for its glaucoma insert VS101 (Eye-D latanoprost insert), demonstrating its ability to lower intraocular pressure for 12 weeks with a favorable safety profile.